Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
08 2020
Historique:
received: 12 06 2019
revised: 05 05 2020
accepted: 19 05 2020
pubmed: 5 6 2020
medline: 28 8 2021
entrez: 5 6 2020
Statut: ppublish

Résumé

Liquid biopsies as a minimally invasive approach have the potential to revolutionize molecular diagnostics. Yet, although protocols for sample handling and the isolation of circulating tumor DNA (ctDNA) are numerous, comprehensive guidelines for diagnostics and research considering all aspects of real-life multicenter clinical studies are currently not available. These include limitations in sample volume, transport, and blood collection tubes. We tested the impact of commonly used (EDTA and heparin) and specialized blood collection tubes and storage conditions on the yield and purity of cell-free DNA for the application in down-stream analysis. Moreover, we evaluated the feasibility of a combined workflow for ctDNA and tumor cell genomic testing and parallel flow cytometric analysis of leukocytes. For genomic analyses, EDTA tubes showed good results if stored for a maximum of 4 hours at room temperature or for up to 24 hours when stored at 4°C. Spike-in experiments revealed that EDTA tubes in combination with density gradient centrifugation allowed the parallel isolation of ctDNA, leukocytes, and low amounts of tumor cells (0.1%) and their immunophenotyping by flow cytometry and down-stream genomic analysis by whole genome sequencing. In conclusion, adhering to time and temperature limits allows the use of routine EDTA blood samples for liquid biopsy analyses. We further provide a workflow enabling the parallel analysis of cell-free and cellular features for disease monitoring and for clonal evolution studies.

Identifiants

pubmed: 32497717
pii: S1525-1578(20)30351-2
doi: 10.1016/j.jmoldx.2020.05.006
pii:
doi:

Substances chimiques

Circulating Tumor DNA 0
Heparin 9005-49-6
Edetic Acid 9G34HU7RV0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1070-1086

Subventions

Organisme : Austrian Science Fund FWF
ID : I 4162
Pays : Austria

Informations de copyright

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Teresa Gerber (T)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Sabine Taschner-Mandl (S)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Lisa Saloberger-Sindhöringer (L)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Niko Popitsch (N)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Ellen Heitzer (E)

Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz and Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Graz, Austria.

Volker Witt (V)

Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

René Geyeregger (R)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Caroline Hutter (C)

Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Raphaela Schwentner (R)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Inge M Ambros (IM)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

Peter F Ambros (PF)

Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; Department of Pediatrics, Medical University of Vienna, Vienna, Austria. Electronic address: peter.ambros@ccri.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH